Celularity (CELU) announced that its strategic partner, Genting Berhad, has broken ground on Fontaine Vitale, a stem cell and regenerative medicine facility in the Sanur Special Economic Zone located in Bali, Indonesia. Fontaine Vitale will offer world-class cell therapies focused on wellness, aesthetics, and regenerative medicine to both local and international patients using placenta-derived stem cells manufactured by Celularity in its US facility, according to Genting Berhad’s press release. The new center is expected to commence commercial operations towards the end of 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CELU: